Writer 최고관리자

Date 21-07-19 09:25

Read 98

World’s First Imaging Biomarker for Parkinson’s Disease


OCTOBER 16TH, 2020

Article Title: World’s First Imaging Biomarker for Parkinson’s Disease

For the first in the world, Heuron Co., Ltd. has developed the AI Imaging biomarker for cranial neuropathy that can be used as a screening method for successful clinical trials. The technology is expected to reduce the time and cost of new drug development and increase clinical success rates. According to an industry insider, it can be used as a  

targeted screening technology to maximize the effectiveness of new drugs and will be a clear biomarker to determine the effectiveness of disease mitigation for the pharmaceutical company.

  • First mover in the AI-based diagnosis market: As pioneer in the industry of AI-based diagnosis, we are providing the essential solutions for clinical use and quantification.

  • The world’s first Parkinson’s disease diagnosis : For the first in the world, we developed the most sophisticated AI-based PD diagnostic software for unmet needs in clinical circumstances.

  • Proven technical skills and reliable data: We published 5 SCI papers. Securing significant know-how in the field and testing results confirms the high levels of accuracy, sensitivity, and specificity.

  • Collaboration with major hospitals: Clinical progression at 10 major hospitals including Asan Medical Center and Seoul St. Mary’s hospital in South Korea. We are the most progressive company that works along with the clinical institution among Korean AI companies. Also, our software is compatible with all three major brands of imaging equipment (GE, Siemens, Philips)

‘mPDia’ is the AI software that diagnoses Parkinson’s disease only through MRI (Magnetic Resonance Imaging). Otherwise PET (Positron Emission Tomography) is a golden standard for Parkinson’s disease.

It is an innovative medical device as a new method of diagnosis to improve the efficiency of the medical practice performed by medical staff with artificial intelligence technology.

In addition, Heuron is currently undergoing clinical trials with Ajou University Hospital due to the development of CT-based automatic diagnosis of stroke severity and early diagnosis of stroke and has various pipelines related to cerebral nerve diseases such as MR-based dementia prognosis and tumor tracking solutions.

Shin Dong-hoon, CEO, MD, Ph.D. of Neurology, said, “Heuron is proud to be the world’s first AI software development company in the field of cerebral neuropathy, where no one has been successful. We will be the world’s leading artificial intelligence software company.”

  • Company introduction

Heuron Co., Ltd. is a Healthcare Startup founded in 2017 by Neurology professor, Dr. Dong-Hoon Shin with faculty members of the Department of Neurology, Radiology, and Medical Engineering, as well as doctoral researchers of artificial intelligence(AI) in the Gachon University Medical Device Center.

A medical AI company led by a clinician (MD), raised high attention from the investment industry because of its specialty in the high level of technology in cranial nerve diseases.

In 2017, Dr. Dong-Hoon Shin led the national project funded by the Ministry of Health and Welfare on the development of biomarkers for Parkinson’s disease (funding amount of KRW 1 billion), laying the foundation for the company’s establishment. This gave Heuron the resources they need to raise expectations and develop advanced levels of Artificial Intelligence in Imaging diagnosis expanding its pipeline to the others neurological diseases.

In July 2020, Heuron Co., Ltd. successfully received series B funding, KRW 15 billion, with an accumulated funding amount of KRW 18 billion (USD 17 million).

Contact Email:, website: